drugset / Trial / NCT00275665

The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection.

NCT00275665

RandomizedParallel-groupDouble-blindPrevention

Summary

This study is being done in stem cell transplant recipients to see if taking the drug valganciclovir can prevent or reduce serious cytomegalovirus (CMV) infections that can occur 100 days or later after transplant.

Timeline

Start
2001-11
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Valganciclovir Small molecule